GDA-201 is an off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large B cell lymphomas.

Israeli company Gamida Cell will raise $10 million in an internal round from its shareholders, including an owners’ loan of $4 million. Elbit Medical Technologies, which owns 31.6% of Gamida Cell, will invest $3 million in the round. Gamida Cell develops stem cell therapy products for transplantation and regenerative medicine. It is soon to start a […]